[Trimetazidine therapy in atrio-cochlear disturbances of vascular origin].
Therapeutic effects of TMZ treatment were evaluated in 31 patients with atrio-cochlear disorders caused by an insufficiency of cerebral circulation. It was found that the results of vestibular or cochlear disorders remission was dependent on the time interval between the onset of symptoms and the beginning of trimetazidine therapy. The best results were also found in patients suffering from atrio-cochlear disorders lasting not longer than two years and due to arterial hypertension or cerebral basilar artery insufficiency.
Kozakiewicz
K
K
III Kliniki Kardiologii Sl. AM, Katowicach.
Wróbel
M
M
Petelenz
T
T
Lepkowski
A
A
Skrzypek-Wańha
J
J
Chruściel
T L
TL
D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy*; D015834:Cochlear Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014292:Trimetazidine / Q000627:therapeutic use*; D015837:Vestibular Diseases / Q000188:drug therapy* / Q000209:etiology
D014292:Trimetazidine